Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Biopro Stem Technology has demonstrated safety and efficacy of its autologous stem cell therapies in Ukrainian clinical settings, particularly for vascular disease, diabetes complications, liver cirrhosis, and autoimmune disorders. The company collaborates closely with national medical institutions to advance regenerative medicine using its proprietary ShorDiCell® platform.
Patient outcomes include improved tissue regeneration markers in preclinical studies and positive real-world results reported by patients across several serious chronic conditions.
Awarded the International Star for Quality Gold Category in 2015 for innovation/service quality.
Pipeline breadth: Estimated at least several programs based on multiple indications treated.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BioPro Stem Technology.